Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GLUE
#2226
Monte Rosa Therapeutics, Inc. Common Stock
17.500
0
USD
-0.28%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-0.28%
Monthly Change
+5.87%
6 month change
+54.87%
Year Change
+54.87%
Previous Close
17.550
0
Open
17.500
0
Bid
Ask
Low
17.500
0
High
17.500
0
Volume
99
Markets
US Stock Market
Healthcare
GLUE
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
46.63 M
49.36 M
50.15 M
61.51 M
80.02 M
—
Valuation ratios
Enterprise value
606.12 M
329.1 M
158.28 M
202.62 M
1.12 B
1.81 B
Price to earnings ratio
—
-3.38
-2.17
-7.08
-34.09
36.44
Price to sales ratio
—
646.88
-576.57
6.78
10.53
18.09
Price to cash flow ratio
—
-3.97
-6.7
12.21
-57.13
-36.27
Price to book ratio
—
1.35
1.64
2.3
5.59
6.94
Enterprise value to EBITDA ratio
-8.55
-3.14
-1.17
-2.78
-25.94
18.87
Profitability ratios
Return on assets %
-0.2
-0.32
-0.45
-0.17
-0.09
-0.08
Return on equity %
-0.21
-0.4
-0.76
-0.33
-0.17
-0.18
Return on invested capital %
-843.49
-259.65
-266.73
-192.35
-149.4
-302.96
Gross margin %
100
100
100
100
100
400
Operating margin %
40.72 K
-19.79 K
28.16 K
-107.26
-43.83
-2 061.14
EBITDA margin %
39.63 K
-18.45 K
26.54 K
-96.52
-35.05
-1 859.83
Net margin %
41.32 K
-19.1 K
26.59 K
-96.14
-31.23
-1 868.84
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
20.96
10.79
5.07
2.4
6.12
25.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0
0
-0
0.2
0.28
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-1.96
-0.85
0.57
-0.27
-0.27
EBIT per share
—
-2.37
-2.8
-1.1
-0.65
-0.66
EBITDA per share
—
-2.22
-2.63
-0.99
-0.52
-0.5
Total debt per share
—
—
—
—
—
—
Cash per share
—
1.16
2.49
3.03
4.54
13.77
Net current asset value per share
—
5.84
4.6
5.11
4.73
17.26
Tangible book value per share
—
5.75
3.49
3.02
2.81
12.37
Working capital per share
—
5.3
3.69
2.98
3.96
14.52
Book value per share
—
5.75
3.49
3.02
2.81
12.37
News
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics earnings on deck amid revenue decline
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa shares rise on prostate cancer trial results
Monte Rosa reports positive trial data for prostate cancer drug
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler
Monte Rosa Therapeutics prices $300 million public offering
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug